{"name":"DOW PHARM","slug":"dow-pharm","ticker":"","exchange":"","domain":"dowpharm.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"High Strength IDP-108","genericName":"High Strength IDP-108","slug":"high-strength-idp-108","indication":"Other","status":"phase_2"},{"name":"IDP-118 Low Strength","genericName":"IDP-118 Low Strength","slug":"idp-118-low-strength","indication":"Other","status":"phase_1"},{"name":"Low Strength IDP-107","genericName":"Low Strength IDP-107","slug":"low-strength-idp-107","indication":"Other","status":"phase_2"},{"name":"Low Strength IDP-108","genericName":"Low Strength IDP-108","slug":"low-strength-idp-108","indication":"Other","status":"phase_2"},{"name":"IDP-115","genericName":"IDP-115","slug":"idp-115","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"IDP-108","genericName":"IDP-108","slug":"idp-108","indication":"Type 2 diabetes","status":"phase_3"},{"name":"IDP-110","genericName":"IDP-110","slug":"idp-110","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"High Strength IDP-108","genericName":"High Strength IDP-108","slug":"high-strength-idp-108","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IDP-108","genericName":"IDP-108","slug":"idp-108","phase":"phase_3","mechanism":"IDP-108 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"IDP-118 Low Strength","genericName":"IDP-118 Low Strength","slug":"idp-118-low-strength","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Low Strength IDP-107","genericName":"Low Strength IDP-107","slug":"low-strength-idp-107","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Low Strength IDP-108","genericName":"Low Strength IDP-108","slug":"low-strength-idp-108","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IDP-110","genericName":"IDP-110","slug":"idp-110","phase":"phase_3","mechanism":"IDP-110 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"IDP-115","genericName":"IDP-115","slug":"idp-115","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":7,"phaseCounts":{"phase_2":4,"phase_3":2,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}